About Vaxcyte
Vaxcyte is a publicly listed company based in Foster City (United States) founded in 2013 by Jeff Fairman. Vaccines for infectious diseases are developed using cell-free protein synthesis. Vaxcyte has raised $347 million across 8 funding rounds from investors including TPG, HHS and Janus Henderson Investors. The company has 414 employees. Vaxcyte offers products and services including VAX-31 and VAX-24. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Diversified. Its legal entity is VAXCYTE, INC. Its competitors include Vir Biotechnology, Cidara Therapeutics and StrideBio; 3 of its 3 listed competitors have raised funding.
Company details
Vaxcyte was founded in 2013 in Foster City, United States, within the biotechnology sector. Focus is placed on developing vaccines against infectious diseases through the XpressCF platform and proprietary knowledge for protein carriers and antigens. Site-specific conjugation is employed to create building blocks for pneumococcal conjugate vaccines like VAS-24. Efforts target invasive pneumococcal diseases, otitis media, strep infections, and periodontitis.
- Headquarters Foster City, United States
- Employees 414
- Founders Jeff Fairman
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website vaxcyte.com
- Social LinkedIn
- Legal Name Vaxcyte, Inc.
- Net Profit-$766.63 M (USD)-65.25as on Dec 31, 2025
- EBITDA-$898.82 M (USD)-62.33as on Dec 31, 2025
- Total Equity Funding$347M (USD)
in 8 rounds
- Latest Funding Round$110M (USD), Series D
Apr 2020
- InvestorsTPG
& 12 more
- Employee Count414
Products & Services of Vaxcyte
Vaxcyte offers a comprehensive portfolio of products and services, including VAX-31 and VAX-24.
Vaccine designed to prevent invasive pneumococcal disease in children and adults.
Vaccine for protection against pneumococcal infections through advanced immunogenicity.
Funding Insights of Vaxcyte
Vaxcyte has successfully raised a total of $347M across 8 strategic funding rounds. The most recent funding activity was a Series D round of $110 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $347M
- Total Rounds 8
- Last Round Series D — $110M
- First Round $2M
(Dec 2013)
- Investors Count 13
All 8 funding rounds of Vaxcyte with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2020 | $110M | Series D | – | RA Capital Management, Janus Henderson Investors | |
| Sep 2019 | $1.6M | Grant | – | – | |
| Jun 2018 | $85M | Series C | – | TPG | |
| Mar 2017 | $64M | Series B | – | – | |
| Mar 2017 | $64M | Series B | – | Frazier Healthcare Partners | |
| Jul 2016 | $196,063 | Grant | – | – | |
| Jul 2015 | $22M | Series A | – | Abingworth | |
| Dec 2013 | $2M | Seed | – | – | – |
13 investors in total: 13 institutional.
Investors in Vaxcyte
Vaxcyte has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include TPG, HHS and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Venture capital investments are made in life sciences companies. | ctisciences.com | Montreal, Canada | ||
Early-stage life science focused VC firm investing in geographies such as Europe and the US | medicxi.com | London, United Kingdom | ||
Corporate-backed venture capital firm focused on the healthcare sector | roche.com/venturefund.htm | |||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States |
Investor details for Vaxcyte
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vaxcyte
202 people are tracked at Vaxcyte (90 in leadership, 12 in board & advisors, 100 in team); the tracked headcount is 414.
| Name | Role | Group |
|---|---|---|
Jeff Fairman | Co-Founder & VP | Leadership |
Marc Wong | Director | Leadership |
Andy Cheung | Associate Director, Polysaccharide MFG | Leadership |
David Sek | Associate Director, Global Drug Product Commercialization | Leadership |
Amanda Wolf | Associate Director, Global Drug Product Commercialization | Leadership |
Allyson Plyler | Director, QA Operations | Leadership |
Neeraj Kapoor | Director / Scientific Lead, Group A Strep And Periodontitis Vaccines | Leadership |
Peter Davey | Executive Director, Polysaccharide PD And Clinical MFG | Leadership |
Karen Alderete | Executive Director, Human Resources | Leadership |
Krystle Hester | Associate Director, Strategic Sourcing | Leadership |
Kristen Boles | Associate Director Quality Control | Leadership |
Mollie Jacobs | Associate Director, Downstream Development For Protein Development And Manufacturing | Leadership |
Donna Luisi | Senior Director Of Drug Product Global Commercialization | Leadership |
Joshua Mu | Associate Director, Global Manufacturing Inventory Accounting | Leadership |
Meadow Stokes | Sr. Director Business Process Development | Leadership |
Carla Vidal | Commercial Packaging Director | Leadership |
Steve Jones | Head Of Commercialization Capabilities And Strategic Projects | Leadership |
Michael Ragone | Senior Director, Supply Chain | Leadership |
Jeannie Chun | Senior Human Resources Business Partner | Leadership |
Ania Bouhoune | Head Of Qms, Vaxcyte Switzerland | Leadership |
182 more people are available in the full profile.
Complete people profiles for Vaxcyte
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Vaxcyte
Vaxcyte is a publicly listed company on the NASDAQ with ticker symbol PCVX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Jun 2020
- Listed onNASDAQ: PCVX
- Listed entityVaxcyte, Inc.
- Exchange sectorHealth technology
- ISINUS92243G1085
- Share price$66.80 (-5.45% on the day) · 2026-10-13
- Market capitalisation$10.25B
- EPS (diluted, trailing year)$-7.71
- Volume (last session)2,645,053
Financials of Vaxcyte
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$766.6M | -$898.8M | |
| 2024 | -$463.9M | -$553.7M | |
| 2023 | -$402.3M | -$382.9M | |
| 2022 | -$223.5M | -$200.1M | |
| 2021 | -$100.1M | -$101.9M |
Detailed financial statements for Vaxcyte
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Vaxcyte
4 dated milestones of Vaxcyte across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Vaxcyte is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series D, of $110.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Vaxcyte
Vaxcyte has 3 listed competitors in our database, 3 of them funded. They include Vir Biotechnology, Cidara Therapeutics and StrideBio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| cidara.com | 2013 | San Diego, United States | $78.35M | 90 | Novel anti-infectives for bacterial and fungal infections are developed. | |
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. |
Detailed competitors of Vaxcyte
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vaxcyte
The website of Vaxcyte (vaxcyte.com) receives about 7.2K visits a month and ranks #1,543,510 among all websites worldwide, #2,045 in Biotechnology and Pharmaceuticals.
- Monthly visits7.2K
▼ 60.8% vs previous month
- Unique visitors4.6K
per month
- Global rank#1,543,510
among all websites
- Category rank#2,045
Health · Biotechnology and Pharmaceuticals
- Bounce rate58%
- Pages per visit1.9
- Average visit2 min 07 sec
- DevicesDesktop 81% · Mobile 19%
Websites whose visitors overlap most with Vaxcyte. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
bioworld.com | bioworld.com | 100% | #311,180 | – |
Top companies in Infectious Diseases
3 companies that operate in the same segment as Vaxcyte (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vaxcyte
Complete news archive for Vaxcyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vaxcyte
Vaxcyte was founded in 2013.
Vaxcyte is headquartered in Foster City, United States. It is registered at Foster City, California, United States.
Vaxcyte is a funded company, having raised a total of $347M across 8 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on Dec 2013.
Vaxcyte has 414 employees.
Vaxcyte was founded in 2013 in Foster City, United States, within the biotechnology sector. Focus is placed on developing vaccines against infectious diseases through the XpressCF platform and proprietary knowledge for protein carriers and antigens. Site-specific conjugation is employed to create building blocks for pneumococcal conjugate vaccines like VAS-24. Efforts target invasive pneumococcal diseases, otitis media, strep infections, and periodontitis.
Vaxcyte's top competitors include Vir Biotechnology, Cidara Therapeutics and StrideBio.
Vaxcyte offers VAX-31 and VAX-24.
Yes, Vaxcyte is publicly traded on NASDAQ under the ticker symbol PCVX.
Vaxcyte has 13 investors. Key investors include TPG, HHS, Janus Henderson Investors, RA Capital, and CARB-X.
Vaxcyte operates through Vaxcyte, Inc..